Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines
Friday, 29 March 2024
Authored Items
Transplant Remains Best Upfront Treatment Option in Newly Diagnosed Myeloma
Dana Taylor
VBCC - April 2016, Vol 7, No 3
in
Hematologic Cancers
A 3-Drug Regimen the Preferred Approach in Newly Diagnosed Multiple Myeloma
Dana Taylor
VBCC - March 2016, Vol 7, No 2
in
Hematologic Malignancies
First-in-Human CAR T-Cell Trial Demonstrates Activity in Multiple Myeloma
Dana Taylor
VBCC - March 2016, Vol 7, No 2
in
Emerging Therapies
Rituximab Boosts Chemotherapy Benefit in Patients with B-Cell Precursor ALL
Dana Taylor
VBCC - March 2016, Vol 7, No 2
in
Hematologic Malignancies
Pembrolizumab Shows Promise in Multiple Myeloma
Dana Taylor
VBCC - March 2016, Vol 7, No 2
in
Hematologic Malignancies
Daratumumab Improves Overall Survival in Multiple Myeloma
Dana Taylor
VBCC - February 2016, Vol 7, No 1
in
Multiple Myeloma
Consistent Benefit Over Time in Elotuzumab Studies
Dana Taylor
VBCC - February 2016, Vol 7, No 1
in
Multiple Myeloma
All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma
Dana Taylor
VBCC - February 2016, Vol 7, No 1
in
Multiple Myeloma
Multiple Myeloma Therapy in 2015: “An Extraordinary Moment in Oncology”
Dana Taylor
VBCC - February 2016, Vol 7, No 1
in
Multiple Myeloma
Using Genetics to Guide Pembrolizumab Therapy in CRC
Dana Taylor
VBCC - October 2015, Vol 6, No 9
in
Emerging Therapies
Assessing the Cost-Effectiveness of Necitumumab in Squamous-Cell Lung Cancer
Dana Taylor
VBCC - August 2015, Vol 6, No 7
in
Economics of Cancer Care
Site of Service Significantly Impacts Cost of Chemotherapy
Dana Taylor
VBCC - August 2015, Vol 6, No 7
in
Economics of Cancer Care
Dissecting the Cost of Targeted Therapies in Oncology
Dana Taylor
VBCC - August 2015, Vol 6, No 7
in
Economics of Cancer Care
Two Large National Personalized Medicine Clinical Trials Are Launched by ASCO and NCI
Dana Taylor
VBCC - July 2015, Vol 6, No 6
in
ASCO 2015 Highlights
Current Cost of Cancer Drugs Does Not Reflect Value, One Oncologist Suggests
Dana Taylor
VBCC - July 2015, Vol 6, No 6
in
ASCO 2015 Highlights
Olaparib-Carboplatin Combination Shows Promise for Patients with Ovarian or Triple-Negative Breast Cancer
Dana Taylor
VBCC - May 2015, Vol 6, No 4
in
AACR Meeting Highlights
Preventing Relapse in Myeloma Carries Economic Benefits, Reduces Overall Costs
Dana Taylor
VBCC - March 2015, Vol 6, No 2
in
Economics of Cancer Care
Promising Therapies in Development for Hematologic Cancers
Dana Taylor
VBCC - February 2015, Vol 6, No 1
in
Emerging Therapies
PD-1 Blockers Show “Amazing” Potential in Hodgkin Lymphoma, Limited Role in Other Hematologic Cancers
Dana Taylor
VBCC - February 2015, Vol 6, No 1
in
ASH 2014 Highlights
Last modified: February 18, 2015
Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines